Last reviewed · How we verify
amoxicillin/clavulanate potassium 1gm
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin. Used for Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.
At a glance
| Generic name | amoxicillin/clavulanate potassium 1gm |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Clavulanate potassium is a beta-lactamase inhibitor that protects amoxicillin from degradation by bacterial beta-lactamase enzymes, thereby extending amoxicillin's spectrum of activity to include beta-lactamase-producing organisms.
Approved indications
- Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reactions (including anaphylaxis)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amoxicillin/clavulanate potassium 1gm CI brief — competitive landscape report
- amoxicillin/clavulanate potassium 1gm updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI